Nimorazole

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Chemotherapeutic agent of the imidazole type.

Half-lifeThis section has been translated automatically.

3 h

IndicationThis section has been translated automatically.

Trichomoniasis, amoebiasis, lambliasis.

Limited indicationThis section has been translated automatically.

Blood formation disorders, application > 10 days, active CNS diseases, severe liver and kidney diseases.

Dosage and method of useThis section has been translated automatically.

  • Amoebiasis, Lambliasis: 2 times 1 g/day p.o. for 5-7 days; children 20-30 mg/kg bw/day.
  • Trichomoniasis: 4 times 500 mg/day p.o. for 7 days (partner treatment!).

Undesirable effectsThis section has been translated automatically.

Allergic reactions, potential carcinogenicity, headache, fatigue, agitation, dizziness, metallic taste, leukopenia, gastrointestinal disorders.

InteractionsThis section has been translated automatically.

Reduced alcohol tolerance, increased bleeding tendency when taking coumarins.

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, imidazole hypersensitivity.

PreparationsThis section has been translated automatically.

Esclama

Authors

Last updated on: 29.10.2020